Skip to main content

Table 3 Patient survival or disease progression by total and stratified analyses

From: Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies

Subgroup OS PFSa
n HR (95% CI) P value n HR (95% CI) P value
Total 10 0.47 (0.31 to 0.72)b <0.001 11 0.87 (0.51 to 1.47)b 0.596
Subtotal by ethnicity       
 White 6 0.67 (0.47 to 0.95)b 0.026 7 1.27 (0.71 to 2.26)b 0.420
 Asian 4 0.35 (0.19 to 0.64)b 0.001 4 0.43 (0.21 to 0.89)b 0.024
Subtotal by disease       
 Brain glioma 3 0.72 (0.52 to 0.99)b 0.045
 Prostate cancer 3 1.25 (0.45 to 3.48)b 0.671
 Esophageal cancer 2 1.50 (0.53 to 4.22)b 0.443
Subtotal by main pathology       
 Adeno 3 0.47 (0.14 to 1.61)b 0.228 7 1.01 (0.55 to 1.89)b 0.965
 SCC 2 0.34 (0.13 to 0.93)b 0.035 2 1.50 (0.53 to 4.22)b 0.443
 Glioblastoma 3 0.72 (0.52 to 0.99)b 0.045
  1. OS, overall survival; PFS, progression-free survival including any of relapse-free survival (RFS), disease-free survival (DFS), and metastasis-free survival (MFS); N, number of studies; HR, hazard ratio; CI, confidence interval; SqCa, squamous carcinoma; Adeno, adenocarcinoma.
  2. aPFS included any of the following: DFS, MFS or RFS.
  3. bThe HRs and 95% CIs of the analyzed studies were pooled by the random-effects model if the P value for heterogeneity was less than 0.10 or I2 was greater than 50%.